Peripheral Neuropathy Trial, Recruiting NCT06964802 Sponsor: Tuba Eryiğit Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06964802
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People who are awake and conscious
  • People who speak and understand Turkish
  • People who have been diagnosed with breast cancer
  • People who are scheduled to receive a chemotherapy medicine called paclitaxel
  • People who answered "no" to a specific section of a symptom questionnaire called the CIPNAT scale (confirm with trial site for details on this assessment)

Who may not be able to join:

  • People whose vibration sensation test suggests nerve damage may already be present (this is checked by a practitioner using a small vibrating tool)
  • People who cannot feel pressure in two or more of three specific areas on the sole of the foot, based on a touch sensitivity test using a thin filament
  • People who have previously experienced nerve damage related to chemotherapy
  • People who have been diagnosed with diabetes
  • People who have open wounds or skin ulcers on their feet
  • People who have a disease affecting the peripheral or central nervous system
  • People who have peripheral vascular disease (a condition affecting blood flow in the blood vessels outside the heart)
  • People who have cancer that has spread to the bones or soft tissue

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +905059683332

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tuba Eryiğit
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
1 December 2025

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

To prevent the development of chemotherapy-associated peripheral neuropathy in patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov